Big pharma leads the way in stock market resurgence

If the theme of the first quarter of 2021 was worry about a stock market correction, the second quarter was all about a resurgence on the back of Alzheimer’s optimism. It seems the FDA, with the controversial approval of Biogen’s Aduhelm, has come to the rescue of biopharma investors.